260 related articles for article (PubMed ID: 2036567)
1. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic implications of the uptake of radiolabelled mIBG for the treatment of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Prog Clin Biol Res; 1991; 366():455-61. PubMed ID: 2068160
[No Abstract] [Full Text] [Related]
4. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
5. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
Gaze MN; Mairs RJ; Boyack SM; Wheldon TE; Barrett A
Br J Cancer; 1992 Dec; 66(6):1048-52. PubMed ID: 1457344
[TBL] [Abstract][Full Text] [Related]
6. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography.
Ott RJ; Tait D; Flower MA; Babich JW; Lambrecht RM
Br J Radiol; 1992 Sep; 65(777):787-91. PubMed ID: 1393416
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
8. A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy.
Rutgers M; Gubbels AA; Hoefnagel CA; Voƻte PA; Smets LA
Prog Clin Biol Res; 1991; 366():471-8. PubMed ID: 2068162
[No Abstract] [Full Text] [Related]
9. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma.
Flower MA; Fielding SL
Phys Med Biol; 1996 Oct; 41(10):1933-40. PubMed ID: 8912372
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine.
Montaldo PG; Carbone R; Cornaglia Ferraris P; Ponzoni M
Cytotechnology; 1993; 11 Suppl 1():S140-3. PubMed ID: 7763744
[TBL] [Abstract][Full Text] [Related]
11. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
12. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
13. Iodine-125-MIBG to treat neuroblastoma: preliminary report.
Sisson JC; Hutchinson RJ; Shapiro B; Zasadny KR; Normolle D; Wieland DM; Wahl RL; Singer DA; Mallette SA; Mudgett EE
J Nucl Med; 1990 Sep; 31(9):1479-85. PubMed ID: 2395016
[TBL] [Abstract][Full Text] [Related]
14. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.
Lashford LS; Moyes J; Ott R; Fielding S; Babich J; Mellors S; Gordon I; Evans K; Kemshead JT
Eur J Nucl Med; 1988; 13(11):574-7. PubMed ID: 3350034
[TBL] [Abstract][Full Text] [Related]
15. Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.
Mairs RJ; Livingstone A; Gaze MN; Wheldon TE; Barrett A
Br J Cancer; 1994 Jul; 70(1):97-101. PubMed ID: 7517173
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children.
Bolster AA; Hilditch TE
Br J Radiol; 1995 Nov; 68(815):1263. PubMed ID: 8542240
[No Abstract] [Full Text] [Related]
17. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
18. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects.
Klingebiel T; Treuner J; Ehninger G; Keller KD; Dopfer R; Feine U; Niethammer D
Cancer Chemother Pharmacol; 1989; 25(2):143-8. PubMed ID: 2598401
[TBL] [Abstract][Full Text] [Related]
19. Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance.
Wafelman AR; Nortier YL; Rosing H; Maessen HJ; Taal BG; Hoefnagel CA; Maes RA; Beijnen JH
Nucl Med Commun; 1995 Sep; 16(9):767-72. PubMed ID: 7478409
[TBL] [Abstract][Full Text] [Related]
20. [131I]metaiodobenzylguanidine in neuroblastoma patients at diagnosis.
Mastrangelo R; Lasorella A; Troncone L; Rufini V; Iavarone A; Riccardi R
J Nucl Biol Med (1991); 1991; 35(4):252-4. PubMed ID: 1823829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]